Regadenoson

• Description :

  Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].

• Product Name Alternative :

  CVT-3146

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Adenosine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Regadenoson.html

• Purity :

  99.59

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(N=C2)C(N)=NC(N4C=C(C=N4)C(NC)=O)=N3)O1

• Molecular Formula :

  C15H18N8O5

• Molecular Weight :

  390.35

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41 (1) :132-9. |[2]Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126 (3) :433-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [313348-27-5]